SAGE Therapeutics, Inc. (US) (SAGE) has disclosed a new risk, in the Innovation / R&D category.
SAGE Therapeutics, Inc., alongside Biogen, faces significant commercialization challenges for ZURZUVAE™, the first oral treatment for postpartum depression (PPD) approved by the FDA. Despite the groundbreaking nature of the treatment, market acceptance is uncertain due to potential reservations from healthcare professionals and patients regarding ZURZUVAE’s safety and tolerability, particularly concerning its impact on driving and breastfeeding. Reimbursement restrictions imposed by payers could further hinder the drug’s uptake, complicating the prescription fulfillment process through specialty pharmacies. These factors collectively cast doubt on SAGE’s ability to meet revenue expectations and achieve broad market penetration for ZURZUVAE as a PPD treatment.
The average SAGE stock price target is $24.91, implying -3.26% downside potential.
To learn more about SAGE Therapeutics, Inc. (US)’s risk factors, click here.
